{"disease":{"id":"recurrent-who-grade-3-glioma","name":"recurrent who grade 3 glioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05859334","title":"Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06410248","title":"Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT06964737","title":"Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}